RecruitingNCT06647134
A Qualitative Assessment of the Severity and Impact of Rheumatic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Immunotherapy
Sponsor
M.D. Anderson Cancer Center
Enrollment
20 participants
Start Date
Sep 11, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
To understand the severity and nature of participants experiences during irAEs following immune checkpoint inhibitor immunotherapy.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a new treatment for people with arthritis, immune checkpoint inhibitors, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06647134
Related Trials
Natural History, Genetics, and Pathophysiology of Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still's Disease, and Related Conditions
NCT035104421 location
Studies of the Natural History of Rheumatic Diseases
NCT000244791 location
Natural History and Development of Spondyloarthritis
NCT014226941 location
DETERMINANTS OF IMMUNOTHERAPY EFFICACY IN ENDOMETRIAL CANCER
NCT076905401 location
Randomized Comparison of PARtial Wrist Fusion With or Without Triquetral Excision (PARTE)
NCT045802255 locations